![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Argent Biopharma Limited | LSE:RGT | London | Ordinary Share | AU0000326647 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.50 | 17.00 | 18.00 | 17.50 | 16.85 | 17.50 | 732 | 08:00:04 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMRGT ReGen's ColostrininTM Approved for Marketing in Turkey <AIM: RGT> 04/05/2010 ReGen Therapeutics Plc ('ReGen' or the 'Company') announces that its Turkish licensee Eczacibasi Ilac Pazarlama A.S ('Eczacibasi')1 has received final approval to market ReGen's nutritional supplement Colostrinin(TM) in the Republic of Turkey. This approval now triggers a $50,000 milestone payment to ReGen. Eczacibasi has placed an order with ReGen for a launch stock of blistered tablets for which ReGen will receive a fee for the active ingredient component. These will be packaged locally by Eczacibasi under the brand-name 'Dyna' with product launch intended in May. Net Revenues to ReGen from Eczacibasi pursuant to the minimum annual purchase commitments in the distribution agreement are estimated to be $52,000 in the first year after final approval is obtained, and $104,000 in the second year. No further details of the launch will be disclosed at this time. This announcement comes only a week after ReGen reported that Colostrinin(TM) is expected to be launched in India during the second quarter of 2010. Launch in these markets are key targets for ReGen as it seeks to achieve sustainable profitability in 2010. Colostrinin(TM) is marketed as a nutritional supplement to 'support healthy brain ageing and cognition in humans'. To date the product is marketed in the US, Canada and Australia under the brand name CogniSure(TM) 2 , in Cyprus3 and Poland 4 under the brand name Cognase(TM) and in the UK5 under the brand name MemoryAid. 1 Eczacibasiwww.eczacibasi.com <http://www.eczacibasi.com/> is a leading turkish industrials group with 40 companies, approximately 9,300 employees and revenues of $3.2bn in 2007. Eczacibasi's Ilac Pazarlama A.S. division is based in Levent-Istanbul, Turkey. 2 Colostrinin(TM) for use as a human nutraceutical is licensed in North America and Australasia to Metagenics Inc. of San Clemente, Californiawww.metagenics.com <http://www.metagenics.com/>). 3 Colostrinin(TM) is distributed in the Republic of Cyprus by Golgi Pharmaceuticals Ltd (www.healthybrainaging.com <http://www.healthybrainaging.com/>) 4 Colostrinin(TM) is is distributed in Poland by Tagerr Polska an affliate of Tagerr a professional services and trading company established in Köln, Germany. (www.cognisure.eu <http://www.cognisure.eu/>) 5 Colostrinin(TM) is distributed in the UK by PRG Nutraceuticals Ltd (www.memoryaid.com <http://www.memoryaid.com/>) For further information, please contact: Percy Lomax ReGen Therapeutics Plc Tel: 020 7153 4920 Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel: 020 7628 3396 David Scott/Nick Bealer Alexander David Securities Limited Tel: 020 7448 9820 . [HUG#1411109]
1 Year Argent Biopharma Chart |
1 Month Argent Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions